InnoCare Pharma's revenue jumps 74.3% in first half of 2025

InnoCare Pharma Limited reported a 74.3% increase in total revenue, reaching RMB731.4 million for the six months ended June 30, 2025, up from RMB419.7 million in the same period of 2024. This growth was primarily driven by a 52.8% increase in Orelabrutinib’s product revenue to RMB637.3 million, and licensing revenue from Prolium. The company's net loss significantly decreased by 86.7% to RMB35.6 million, from RMB268.0 million in the prior year. Cash and related accounts balances stood at approximately RMB7.7 billion as of June 30, 2025.

Key milestones include the approval of Orelabrutinib for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma and tafasitamab for relapsed or refractory DLBCL. The next-generation BCL-2 inhibitor, ICP-248 (mesutoclax), entered two registrational clinical studies, and the ADC platform achieved IND submission and clinical trial approval. ICP-723 received priority review for NTRK gene fusion-positive tumors.

The company further expanded its global footprint through a strategic collaboration with Prolium for ICP-B02 development and commercialization. Orelabrutinib is advancing in global phase III trials for primary and secondary progressive multiple sclerosis, and ICP-332, a TYK2 inhibitor, is in phase III trials for atopic dermatitis.